{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:30:47Z","timestamp":1792539047247,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction\/Objective<\/jats:title>\n                    <jats:p>The primary aim of this study was to evaluate changes in pain-specific and general health-related quality of life in individuals prescribed cannabis-based medicinal products (CBMPs) for hypermobility-associated chronic pain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The case series utilised data from the UK Medical Cannabis Registry. Primary outcomes were changes in Brief Pain Inventory (BPI), Pain Visual Analogue Scale (VAS), Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2), EQ-5D-5L index value, Generalised Anxiety Disorder-7 (GAD-7), and Single-item Sleep Quality Scale (SQS) over 24 months. Repeated measures analysis of variance was used to assess changes over time, with post hoc pairwise comparisons performed for significant findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 240 patients were analysed. Changes were observed across all patient-reported outcome measures (PROMs) on repeated measures analysis of variance (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Post hoc pairwise comparisons for the BPI subscales, SF-MPQ-2 and Pain VAS demonstrated improvement from baseline to all subsequent timepoints (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). By 24 months, 56.67% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009136) and 61.25% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009147) of participants reported clinically significant improvements in BPI severity and interference respectively. Clinically significant improvements were also reported for SF-MPQ-2 (47.08%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009113) and Pain VAS scores (60.00%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009144).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      In this real-world cohort, CBMP treatment was associated with sustained improvements in outcomes for individuals with hypermobility-associated chronic pain. These findings support the need for further controlled studies to determine causality.\n                      <jats:table-wrap>\n                        <jats:table>\n                          <jats:tbody>\n                            <jats:tr>\n                              <jats:td colspan=\"2\">\n                                <jats:bold>Key Points<\/jats:bold>\n                                \u2022\n                                <jats:italic>This 24-month real-world study demonstrates sustained improvements in pain, anxiety, and sleep outcomes for patients with hypermobility-associated chronic pain treated with cannabis-based medicinal products, with approximately 60% achieving clinically meaningful pain reductions<\/jats:italic>\n                                .\u2022\n                                <jats:italic>Cannabis-based medicinal products were associated with reductions in concomitant opioid prescriptions at 12, 18, and 24 months<\/jats:italic>\n                                .\u2022\n                                <jats:italic>This represents the largest and longest-duration observational study of medical cannabis therapy specifically in hypermobility spectrum disorders and Ehlers-Danlos syndrome, addressing a critical evidence gap in chronic pain management<\/jats:italic>\n                                .\u2022\n                                <jats:italic>Adverse events were predominantly mild-to-moderate in severity, with poor baseline sleep quality and current cannabis use identified as positive predictors of pain improvement, informing patient selection and treatment optimisation<\/jats:italic>\n                                .\n                              <\/jats:td>\n                            <\/jats:tr>\n                          <\/jats:tbody>\n                        <\/jats:table>\n                      <\/jats:table-wrap>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10067-026-08166-z","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:18:42Z","timestamp":1780118322000},"page":"4569-4582","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["UK Medical Cannabis Registry: an updated analysis of clinical outcomes of medicinal cannabis therapy for hypermobility-associated chronic pain"],"prefix":"10.1007","volume":"45","author":[{"given":"Mariam","family":"Alemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5871-6501","authenticated-orcid":false,"given":"Simon","family":"Erridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evonne","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"McLachlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Coomber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alia","family":"Darweish Medniuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Guru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Holden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Sajad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Searle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azfer","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Rucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael H.","family":"Sodergren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"issue":"2","key":"8166_CR1","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1136\/pn-2023-003703","volume":"24","author":"FS van Dijk","year":"2024","unstructured":"van Dijk FS, Ghali N, Chandratheva A (2024) Ehlers-Danlos syndromes: importance of defining the type. Pract Neurol 24(2):90\u201397. https:\/\/doi.org\/10.1136\/pn-2023-003703","journal-title":"Pract Neurol"},{"issue":"1","key":"8166_CR2","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/ajmg.c.31554","volume":"175","author":"P Chopra","year":"2017","unstructured":"Chopra P, Tinkle B, Hamonet C, Brock I, Gompel A, Bulbena A et al (2017) Pain management in the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet 175(1):212\u2013219. https:\/\/doi.org\/10.1002\/ajmg.c.31554","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"4","key":"8166_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjpt.2023.100537","volume":"27","author":"J Nijs","year":"2023","unstructured":"Nijs J, De Baets L, Hodges P (2023) Phenotyping nociceptive, neuropathic, and nociplastic pain: who, how, & why? Braz J Phys Ther 27(4):100537. https:\/\/doi.org\/10.1016\/j.bjpt.2023.100537","journal-title":"Braz J Phys Ther"},{"issue":"4","key":"8166_CR4","doi-asserted-by":"publisher","first-page":"429","DOI":"10.36076\/ppj.2020\/23\/429","volume":"23","author":"B Song","year":"2020","unstructured":"Song B, Yeh P, Nguyen D, Ikpeama U, Epstein M, Harrell J (2020) Ehlers-Danlos syndrome: an analysis of the current treatment options. Pain Physician 23(4):429\u2013438","journal-title":"Pain Physician"},{"key":"8166_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f7656","volume":"348","author":"SP Cohen","year":"2014","unstructured":"Cohen SP, Mao J (2014) Neuropathic pain: mechanisms and their clinical implications. BMJ 348:f7656. https:\/\/doi.org\/10.1136\/bmj.f7656","journal-title":"BMJ"},{"issue":"Suppl 1","key":"8166_CR6","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1097\/j.pain.0000000000000428","volume":"157","author":"R Maldonado","year":"2016","unstructured":"Maldonado R, Ba\u00f1os JE, Caba\u00f1ero D (2016) The endocannabinoid system and neuropathic pain. Pain 157(Suppl 1):S23\u2013S32. https:\/\/doi.org\/10.1097\/j.pain.0000000000000428","journal-title":"Pain"},{"issue":"1","key":"8166_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neuron.2012.09.020","volume":"76","author":"PE Castillo","year":"2012","unstructured":"Castillo PE, Younts TJ, Ch\u00e1vez AE, Hashimotodani Y (2012) Endocannabinoid signaling and synaptic function. Neuron 76(1):70\u201381. https:\/\/doi.org\/10.1016\/j.neuron.2012.09.020","journal-title":"Neuron"},{"issue":"3","key":"8166_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.5152\/eurjrheum.2017.17025","volume":"4","author":"N Barrie","year":"2017","unstructured":"Barrie N, Manolios N (2017) The endocannabinoid system in pain and inflammation: its relevance to rheumatic disease. Eur J Rheumatol 4(3):210\u2013218. https:\/\/doi.org\/10.5152\/eurjrheum.2017.17025","journal-title":"Eur J Rheumatol"},{"issue":"20","key":"8166_CR9","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1111\/bph.13250","volume":"172","author":"RB Laprairie","year":"2015","unstructured":"Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM (2015) Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol 172(20):4790\u20134805. https:\/\/doi.org\/10.1111\/bph.13250","journal-title":"Br J Pharmacol"},{"key":"8166_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01259","volume":"9","author":"S Vu\u010dkovi\u0107","year":"2018","unstructured":"Vu\u010dkovi\u0107 S, Srebro D, Vujovi\u0107 KS, Vu\u010deti\u0107 \u010c, Prostran M (2018) Cannabinoids and pain: new insights from old molecules. Front Pharmacol 9:1259. https:\/\/doi.org\/10.3389\/fphar.2018.01259","journal-title":"Front Pharmacol"},{"key":"8166_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1034","volume":"374","author":"L Wang","year":"2021","unstructured":"Wang L, Hong PJ, May C, Rehman Y, Oparin Y, Hong CJ et al (2021) Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials. BMJ 374:n1034. https:\/\/doi.org\/10.1136\/bmj.n1034","journal-title":"BMJ"},{"issue":"1","key":"8166_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0267420","volume":"18","author":"J Barakji","year":"2023","unstructured":"Barakji J, Korang SK, Feinberg J, Maagaard M, Mathiesen O, Gluud C, Jakobsen JC (2023) Cannabinoids versus placebo for pain: a systematic review with meta-analysis and Trial Sequential Analysis. PLoS One 18(1):e0267420. https:\/\/doi.org\/10.1371\/journal.pone.0267420","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"8166_CR13","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1097\/j.pain.0000000000001929","volume":"162","author":"E Fisher","year":"2021","unstructured":"Fisher E, Moore RA, Fogarty AE, Finn DP, Finnerup NB, Gilron I et al (2021) Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain 162(Suppl 1):S45\u2013S66. https:\/\/doi.org\/10.1097\/j.pain.0000000000001929","journal-title":"Pain"},{"issue":"3","key":"8166_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.70024","volume":"7","author":"M Dickinson","year":"2025","unstructured":"Dickinson M, Erridge S, Warner-Levy J, Clarke E, McLachlan K, Coomber R et al (2025) UK medical cannabis registry: an analysis of outcomes of medical cannabis therapy for hypermobility-associated chronic pain. ACR Open Rheumatol 7(3):e70024. https:\/\/doi.org\/10.1002\/acr2.70024","journal-title":"ACR Open Rheumatol"},{"issue":"5","key":"8166_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8","journal-title":"J Chronic Dis"},{"key":"8166_CR16","unstructured":"Joint Formulary Committee (2023) British national formulary [Internet]. London: BMJ Group and Pharmaceutical Press, [cited 2025 Apr 29]. Available from: https:\/\/bnf.nice.org.uk\/"},{"issue":"2","key":"8166_CR17","first-page":"129","volume":"23","author":"CS Cleeland","year":"1994","unstructured":"Cleeland CS, Ryan KM (1994) Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap 23(2):129\u2013138","journal-title":"Ann Acad Med Singap"},{"issue":"2","key":"8166_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","volume":"9","author":"RH Dworkin","year":"2008","unstructured":"Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT et al (2008) Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 9(2):105\u2013121. https:\/\/doi.org\/10.1016\/j.jpain.2007.09.005","journal-title":"J Pain"},{"issue":"1\u20132","key":"8166_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.pain.2009.02.007","volume":"144","author":"RH Dworkin","year":"2009","unstructured":"Dworkin RH, Turk DC, Revicki DA, Harding G, Coyne KS, Peirce-Sandner S et al (2009) Development and initial validation of an expanded and revised version of the Short-form McGill Pain Questionnaire (SF-MPQ-2). Pain 144(1\u20132):35\u201342. https:\/\/doi.org\/10.1016\/j.pain.2009.02.007","journal-title":"Pain"},{"issue":"Suppl 11","key":"8166_CR20","doi-asserted-by":"publisher","first-page":"S240","DOI":"10.1002\/acr.20543","volume":"63","author":"GA Hawker","year":"2011","unstructured":"Hawker GA, Mian S, Kendzerska T, French M (2011) Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken) 63(Suppl 11):S240\u2013S252. https:\/\/doi.org\/10.1002\/acr.20543","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"8166_CR21","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D et al (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20(10):1727\u20131736. https:\/\/doi.org\/10.1007\/s11136-011-9903-x","journal-title":"Qual Life Res"},{"issue":"5","key":"8166_CR22","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B van Hout","year":"2012","unstructured":"van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D et al (2012) Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 15(5):708\u2013715. https:\/\/doi.org\/10.1016\/j.jval.2012.02.008","journal-title":"Value Health"},{"issue":"10","key":"8166_CR23","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","volume":"166","author":"RL Spitzer","year":"2006","unstructured":"Spitzer RL, Kroenke K, Williams JB, L\u00f6we B (2006) A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 166(10):1092\u20131097. https:\/\/doi.org\/10.1001\/archinte.166.10.1092","journal-title":"Arch Intern Med"},{"key":"8166_CR24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jad.2020.01.032","volume":"265","author":"A Toussaint","year":"2020","unstructured":"Toussaint A, H\u00fcsing P, Gumz A, Wingenfeld K, H\u00e4rter M, Schramm E et al (2020) Sensitivity to change and minimal clinically important difference of the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7). J Affect Disord 265:395\u2013401. https:\/\/doi.org\/10.1016\/j.jad.2020.01.032","journal-title":"J Affect Disord"},{"issue":"11","key":"8166_CR25","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.5664\/jcsm.7478","volume":"14","author":"E Snyder","year":"2018","unstructured":"Snyder E, Cai B, DeMuro C, Morrison MF, Ball W (2018) A new single-item sleep quality scale: results of psychometric evaluation in patients with chronic primary insomnia and depression. J Clin Sleep Med 14(11):1849\u20131857. https:\/\/doi.org\/10.5664\/jcsm.7478","journal-title":"J Clin Sleep Med"},{"issue":"1","key":"8166_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000146","volume":"1","author":"E Rampakakis","year":"2015","unstructured":"Rampakakis E, Ste-Marie PA, Sampalis JS, Karellis A, Shir Y, Fitzcharles MA (2015) Real-life assessment of the validity of patient global impression of change in fibromyalgia. RMD Open 1(1):e000146. https:\/\/doi.org\/10.1136\/rmdopen-2015-000146","journal-title":"RMD Open"},{"key":"8166_CR27","unstructured":"National Cancer Institute (2009) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 [Internet]. Bethesda (MD): U.S. Department of Health and Human Services, [cited 2025 Apr 28]. Available from: https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/Archive\/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf"},{"issue":"4","key":"8166_CR28","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1370\/afm.1375","volume":"10","author":"JA Zweifler","year":"2012","unstructured":"Zweifler JA (2012) Objective evidence of severe disease: Opioid use in chronic pain. Ann Fam Med 10(4):366\u2013368. https:\/\/doi.org\/10.1370\/afm.1375","journal-title":"Ann Fam Med"},{"issue":"1","key":"8166_CR29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2147\/tcrm.s1928","volume":"4","author":"EB Russo","year":"2008","unstructured":"Russo EB (2008) Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag 4(1):245\u2013259. https:\/\/doi.org\/10.2147\/tcrm.s1928","journal-title":"Ther Clin Risk Manag"},{"issue":"9","key":"8166_CR30","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1038\/npp.2017.51","volume":"42","author":"S Nielsen","year":"2017","unstructured":"Nielsen S, Sabioni P, Trigo JM, Ware MA, Betz-Stablein BD, Murnion B et al (2017) Opioid-sparing effect of cannabinoids: A systematic review and meta-analysis. Neuropsychopharmacology 42(9):1752\u20131765. https:\/\/doi.org\/10.1038\/npp.2017.51","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"8166_CR31","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2217\/pmt-2018-0051","volume":"9","author":"SP Khan","year":"2019","unstructured":"Khan SP, Pickens TA, Berlau DJ (2019) Perspectives on cannabis as a substitute for opioid analgesics. Pain Manag 9(2):191\u2013203. https:\/\/doi.org\/10.2217\/pmt-2018-0051","journal-title":"Pain Manag"},{"issue":"7","key":"8166_CR32","doi-asserted-by":"publisher","DOI":"10.5435\/JAAOSGlobal-D-22-00055","volume":"6","author":"D Mangual-P\u00e9rez","year":"2022","unstructured":"Mangual-P\u00e9rez D, Tresgallo-Par\u00e9s R, Ram\u00edrez-Gonz\u00e1lez M, Torres-Lugo NJ, Rivera-Dones A, Rivera-Rodr\u00edguez G et al (2022) Patient experience and perspective on medical cannabis as an alternative for musculoskeletal pain management. JAAOS Glob Res Rev 6(7):e22.00055. https:\/\/doi.org\/10.5435\/JAAOSGlobal-D-22-00055","journal-title":"JAAOS Glob Res Rev"},{"issue":"3","key":"8166_CR33","doi-asserted-by":"publisher","first-page":"406","DOI":"10.15288\/jsad.2015.76.406","volume":"76","author":"BE Perron","year":"2015","unstructured":"Perron BE, Bohnert K, Perone AK, Bonn-Miller MO, Ilgen M (2015) Use of prescription pain medications among medical cannabis patients: Comparisons of pain levels, functioning, and patterns of alcohol and other drug use. J Stud Alcohol Drugs 76(3):406\u2013413. https:\/\/doi.org\/10.15288\/jsad.2015.76.406","journal-title":"J Stud Alcohol Drugs"},{"issue":"8","key":"8166_CR34","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.7326\/M21-4520","volume":"175","author":"MS McDonagh","year":"2022","unstructured":"McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D et al (2022) Cannabis-based products for chronic pain: A systematic review. Ann Intern Med 175(8):1143\u20131153. https:\/\/doi.org\/10.7326\/M21-4520","journal-title":"Ann Intern Med"},{"issue":"6","key":"8166_CR35","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1097\/j.pain.0000000000002466","volume":"163","author":"J Vela","year":"2022","unstructured":"Vela J, Dreyer L, Petersen KK, Arendt-Nielsen L, Duch KS, Kristensen S (2022) Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind, placebo-controlled trial. Pain 163(6):1206\u20131214. https:\/\/doi.org\/10.1097\/j.pain.0000000000002466","journal-title":"Pain"},{"issue":"4","key":"8166_CR36","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1097\/j.pain.0000000000001464","volume":"160","author":"T van de Donk","year":"2019","unstructured":"van de Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, van Velzen M (2019) An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain 160(4):860\u2013869. https:\/\/doi.org\/10.1097\/j.pain.0000000000001464","journal-title":"Pain"},{"issue":"1","key":"8166_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-14-136","volume":"14","author":"KK Kedzior","year":"2014","unstructured":"Kedzior KK, Laeber LT (2014) A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population: a meta-analysis of 31 studies. BMC Psychiatry 14(1):136. https:\/\/doi.org\/10.1186\/1471-244X-14-136","journal-title":"BMC Psychiatry"},{"key":"8166_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102455","volume":"69","author":"DT Myran","year":"2024","unstructured":"Myran DT, Harrison LD, Pugliese M, Tanuseputro P, Gaudreault A, Fiedorowicz JG et al (2024) Development of an anxiety disorder following an emergency department visit due to cannabis use: a population-based cohort study. EClinicalMedicine 69:102455. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102455","journal-title":"EClinicalMedicine"},{"issue":"4","key":"8166_CR39","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40429-022-00450-7","volume":"9","author":"SD Lichenstein","year":"2022","unstructured":"Lichenstein SD (2022) THC, CBD, and anxiety: a review of recent findings on the anxiolytic and anxiogenic effects of cannabis\u2019 primary cannabinoids. Curr Addict Rep 9(4):473\u2013485. https:\/\/doi.org\/10.1007\/s40429-022-00450-7","journal-title":"Curr Addict Rep"},{"issue":"7","key":"8166_CR40","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1197\/j.aem.2006.11.038","volume":"14","author":"CD Newgard","year":"2007","unstructured":"Newgard CD, Haukoos JS (2007) Advanced statistics: missing data in clinical research - Part 2: multiple imputation. Acad Emerg Med 14(7):669\u2013678. https:\/\/doi.org\/10.1197\/j.aem.2006.11.038","journal-title":"Acad Emerg Med"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08166-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08166-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08166-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:28:37Z","timestamp":1783398517000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08166-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["8166"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08166-z","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"28 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Central Bristol Research Ethics Committee (reference: 22\/SW\/0145). Participants all provided informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent"}},{"value":"MA has no conflicts of interest to declare. All other authors are employed by or work on a consultancy basis for Curaleaf Clinic.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}